Cargando…
A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants
As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continue to emerge and spread around the world, antibodies and vaccines to confer broad and potent neutralizing activity are urgently needed. Through the isolation and characterization of monoclonal antibodies (mAbs) from indiv...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710476/ https://www.ncbi.nlm.nih.gov/pubmed/34966387 http://dx.doi.org/10.3389/fimmu.2021.766821 |
_version_ | 1784623162274611200 |
---|---|
author | Shan, Sisi Mok, Chee Keng Zhang, Shuyuan Lan, Jun Li, Jizhou Yang, Ziqing Wang, Ruoke Cheng, Lin Fang, Mengqi Aw, Zhen Qin Yu, Jinfang Zhang, Qi Shi, Xuanling Zhang, Tong Zhang, Zheng Wang, Jianbin Wang, Xinquan Chu, Justin Jang Hann Zhang, Linqi |
author_facet | Shan, Sisi Mok, Chee Keng Zhang, Shuyuan Lan, Jun Li, Jizhou Yang, Ziqing Wang, Ruoke Cheng, Lin Fang, Mengqi Aw, Zhen Qin Yu, Jinfang Zhang, Qi Shi, Xuanling Zhang, Tong Zhang, Zheng Wang, Jianbin Wang, Xinquan Chu, Justin Jang Hann Zhang, Linqi |
author_sort | Shan, Sisi |
collection | PubMed |
description | As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continue to emerge and spread around the world, antibodies and vaccines to confer broad and potent neutralizing activity are urgently needed. Through the isolation and characterization of monoclonal antibodies (mAbs) from individuals infected with SARS-CoV-2, we identified one antibody, P36-5D2, capable of neutralizing the major SARS-CoV-2 variants of concern. Crystal and electron cryo-microscopy (cryo-EM) structure analyses revealed that P36-5D2 targeted to a conserved epitope on the receptor-binding domain of the spike protein, withstanding the three key mutations—K417N, E484K, and N501Y—found in the variants that are responsible for escape from many potent neutralizing mAbs, including some already approved for emergency use authorization (EUA). A single intraperitoneal (IP) injection of P36-5D2 as a prophylactic treatment completely protected animals from challenge of infectious SARS-CoV-2 Alpha and Beta. Treated animals manifested normal body weight and were devoid of infection-associated death up to 14 days. A substantial decrease of the infectious virus in the lungs and brain, as well as reduced lung pathology, was found in these animals compared to the controls. Thus, P36-5D2 represents a new and desirable human antibody against the current and emerging SARS-CoV-2 variants. |
format | Online Article Text |
id | pubmed-8710476 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87104762021-12-28 A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants Shan, Sisi Mok, Chee Keng Zhang, Shuyuan Lan, Jun Li, Jizhou Yang, Ziqing Wang, Ruoke Cheng, Lin Fang, Mengqi Aw, Zhen Qin Yu, Jinfang Zhang, Qi Shi, Xuanling Zhang, Tong Zhang, Zheng Wang, Jianbin Wang, Xinquan Chu, Justin Jang Hann Zhang, Linqi Front Immunol Immunology As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continue to emerge and spread around the world, antibodies and vaccines to confer broad and potent neutralizing activity are urgently needed. Through the isolation and characterization of monoclonal antibodies (mAbs) from individuals infected with SARS-CoV-2, we identified one antibody, P36-5D2, capable of neutralizing the major SARS-CoV-2 variants of concern. Crystal and electron cryo-microscopy (cryo-EM) structure analyses revealed that P36-5D2 targeted to a conserved epitope on the receptor-binding domain of the spike protein, withstanding the three key mutations—K417N, E484K, and N501Y—found in the variants that are responsible for escape from many potent neutralizing mAbs, including some already approved for emergency use authorization (EUA). A single intraperitoneal (IP) injection of P36-5D2 as a prophylactic treatment completely protected animals from challenge of infectious SARS-CoV-2 Alpha and Beta. Treated animals manifested normal body weight and were devoid of infection-associated death up to 14 days. A substantial decrease of the infectious virus in the lungs and brain, as well as reduced lung pathology, was found in these animals compared to the controls. Thus, P36-5D2 represents a new and desirable human antibody against the current and emerging SARS-CoV-2 variants. Frontiers Media S.A. 2021-12-13 /pmc/articles/PMC8710476/ /pubmed/34966387 http://dx.doi.org/10.3389/fimmu.2021.766821 Text en Copyright © 2021 Shan, Mok, Zhang, Lan, Li, Yang, Wang, Cheng, Fang, Aw, Yu, Zhang, Shi, Zhang, Zhang, Wang, Wang, Chu and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Shan, Sisi Mok, Chee Keng Zhang, Shuyuan Lan, Jun Li, Jizhou Yang, Ziqing Wang, Ruoke Cheng, Lin Fang, Mengqi Aw, Zhen Qin Yu, Jinfang Zhang, Qi Shi, Xuanling Zhang, Tong Zhang, Zheng Wang, Jianbin Wang, Xinquan Chu, Justin Jang Hann Zhang, Linqi A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants |
title | A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants |
title_full | A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants |
title_fullStr | A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants |
title_full_unstemmed | A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants |
title_short | A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants |
title_sort | potent and protective human neutralizing antibody against sars-cov-2 variants |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710476/ https://www.ncbi.nlm.nih.gov/pubmed/34966387 http://dx.doi.org/10.3389/fimmu.2021.766821 |
work_keys_str_mv | AT shansisi apotentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT mokcheekeng apotentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT zhangshuyuan apotentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT lanjun apotentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT lijizhou apotentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT yangziqing apotentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT wangruoke apotentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT chenglin apotentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT fangmengqi apotentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT awzhenqin apotentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT yujinfang apotentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT zhangqi apotentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT shixuanling apotentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT zhangtong apotentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT zhangzheng apotentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT wangjianbin apotentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT wangxinquan apotentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT chujustinjanghann apotentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT zhanglinqi apotentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT shansisi potentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT mokcheekeng potentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT zhangshuyuan potentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT lanjun potentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT lijizhou potentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT yangziqing potentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT wangruoke potentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT chenglin potentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT fangmengqi potentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT awzhenqin potentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT yujinfang potentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT zhangqi potentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT shixuanling potentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT zhangtong potentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT zhangzheng potentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT wangjianbin potentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT wangxinquan potentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT chujustinjanghann potentandprotectivehumanneutralizingantibodyagainstsarscov2variants AT zhanglinqi potentandprotectivehumanneutralizingantibodyagainstsarscov2variants |